All News
Staggering stats after a #osteoporosis hip fracture!
40% cannot walk independently
30% have a permanent disability
20% mortality in surgically fixed hip
40% mortality if not surgically fixed. -Dr. M Humphrey #ACR22 @rheumnow https://t.co/DSYQjDw6pW
TheDaoIndex KDAO2011 ( View Tweet)
Dose Matters!
Steroid doses as little as 2.5 mg/day when taken chronically increase risk for fractures #ACR22 @rheumnow https://t.co/fIocJtebkI
TheDaoIndex KDAO2011 ( View Tweet)
Morales et al. AUR200, novel BAFF/APRIL inhibitor. Looking promising in pre-clinical and animal models. We will wait and see! @RheumNow #ACR22 Abstr#1629 https://t.co/htmX2GHV3X https://t.co/jvhFdx2c52
Richard Conway RichardPAConway ( View Tweet)
MOA of how steroids cause #osteoporosis #ACR22 @rheumnow https://t.co/k6MvftH4AV
TheDaoIndex KDAO2011 ( View Tweet)
Lin et al. Genetic risk (HR 2.3 women, 2.63 men) and lifestyle (HR 5.7 for women, 3.7 for men) both individual contributors and synergistic (HR 9.1 women, 8.7 men) in gout development in both men and women. Modifiable! @RheumNow #ACR22 Abstr#1633 https://t.co/51KPgfXn1w https://t.co/gOU7DfOKvt
Richard Conway RichardPAConway ( View Tweet)
PMR is no a disease of vague shoulder and hip pain.
It's something much more specific:
a chronic inflammatory disease of musculotendinous structures.
We're starting to understand the real story.
@drceowen lays it out for #ACR22 this morning
@EBRheum @SattuiSEMD @RheumNow https://t.co/thqtCwSULM
David Liew drdavidliew ( View Tweet)
Bimekizumab (BKZ) in AxSpA to Wk52
◦ sustained efficacy
◦ suppression of inflammation
◦ improvements in function and quality of life
◦ no new safety signals were observed
◦ consistent with the safety profileWk24 data
Baraliakos #L14 https://t.co/gk23g4vqQl #ACR22 @RheumNow
Dr. Antoni Chan synovialjoints ( View Tweet)
Fernandes et al. CPPD assoc increased nephrolithiasis. 8.06% vs 4.88%; p<0.0001. @RheumNow #ACR22 Abstr#1819 https://t.co/o8Afmcc429 https://t.co/3EoOXpqpGN
Richard Conway RichardPAConway ( View Tweet)
Chen et al. Appendicitis associated increased risk incident SLE in population-based case-control study from Taiwan. HR 2.04 @RheumNow #ACR22 Abstr#1750 https://t.co/L9dTpMdHNP https://t.co/mEHeL6JnuE
Richard Conway RichardPAConway ( View Tweet)
Parperis et al. Cypriot population based study. ACS in CPPD assoc longer LOS, and increased mortality 6.9% vs 5.6% (p<0.001). @RheumNow #ACR22 Abstr#1817 https://t.co/uWv67aZa9L https://t.co/3oRFXREcYx
Richard Conway RichardPAConway ( View Tweet)
Helget et al. Subanalysis of STOP Gout. Allopurinol and febuxostat equal efficacy in CKD 3. More AKI with allopurinol 8.3% vs 2.4%. @RheumNow #ACR22 Abstr#1829 https://t.co/Z4JqYp4mTT https://t.co/xd8VGJVkNo
Richard Conway RichardPAConway ( View Tweet)
Low dose #glucocorticoids in rheumatic diseases can lower bone mass and increase # even 2.5 mg #prednisone. The change in #BMD was more predictive of fracture not absolute BMD. L01 #ACR22 #ACRBest @RheumNow https://t.co/MbTk0L4DoK
Janet Pope Janetbirdope ( View Tweet)
Mortality in patients with SpA
Abstract #0569 #ACR22 @RheumNow
✏️systematic review/meta-analysis of 19 studies
✋No increased mortality in patients with PsA compared to gen. pop.
🦠Infection, 🫀CV, and 🫁 pulm. specific mortality sig. higher in PsA patients
Catherine Sims, MD DrCassySims ( View Tweet)
How do we know what PMR is all about?
Imaging has helped enormously, and every step of the way, imaging has got better and better. Specific findings which reveal the culpable pathology.
@drceowen #ACR22 @RheumNow https://t.co/4OOOk0F3jW
David Liew drdavidliew ( View Tweet)
NSAIDs and CV risk in Inflammatory Arthritis
Dr. Richard Conway discusses abstract 1207, being presented #ACR22 meeting.
https://t.co/CjU2YbA3tk https://t.co/bHE4xw2IRF
Links:
Dr. John Cush RheumNow ( View Tweet)
#ACR2022 L07: Telitacicept - anti-BlyS and APRIL in SLE
335 pts P3 52 wk study TEL 160 mg SQ q7d vs PBO
83% SRI4 response in TEL vs 38% PBO (p<0.001)
As early as w4, sustained to w52
Most common AEs: URIs, decr IgG/IgM, injxn site rxn, UTI
@RheumNow #ACRBest https://t.co/UpEwEaonDO
Eric Dein ericdeinmd ( View Tweet)
Khanna et al Transdermal NaHCO₃ in gout flare. N=98. Response rate D7 95% vs 79% (p=0.01). Lower rescue med, 6% vs 20%. @RheumNow #ACR22 Abstr#1787 https://t.co/DWtlvjzBHw https://t.co/DOk993gCwz
Richard Conway RichardPAConway ( View Tweet)
Joy et al. Disease activity rather than steroid use increases risk of diabetes in RA in BeST study over 10 years. @RheumNow #ACR22 Abstr#1987 https://t.co/VT2eb3Q4m9 https://t.co/kquZ70o9bU
Richard Conway RichardPAConway ( View Tweet)
L08 #ACR22 TIX/CIL (Evusheld) in Rheum Pts
157 pts, f/u 154 days
24 breakthrough COVID ifns (15%)
2 pts required hospitalization, rest had mild-mod symptoms
No SAEs (CVD)
@RheumNow
Eric Dein ericdeinmd ( View Tweet)
#ACR22 Best in PsA and SpA - new Rxs, unraveling responses to Rx by sex/gender. X-ray inhibition w SpA drugs is a reality. Nice peeps working in these areas @RheumNow @ACRheum https://t.co/8VfdyyHPZi
Janet Pope Janetbirdope ( View Tweet)